Effect of Fertility-sparing Therapy of Early Endometrial Cancer

Effect of Fertility-sparing Therapy of Early Endometrial Cancer

The purpose of this study is to investigate the effect of Fertility-sparing Therapy of Early Endometrial Cancer.

This is a prospective, multi center, open, randomized, controlled clinical trial. All endometrial cancer (EC) or atypical hyperplasia (AH) patients who met the fertility-sparing indications in the hospitals involved in this study were recruited. Then the investigators conducted assessment, treatment and follow up according to the standard procedure. General information, therapeutic regimen, side effects, oncological and pregnant results were collected for risk factors analysis.

Inclusion Criteria:

• ages of no more than 40
• with a strong desire of fertility preservation
• International Federation of Gynecology and Obstetrics (FIGO) 2009 stage Ⅰa grade 1~2 with lesion confined in endometrium
• pathology expression of progestin receptors (PRs) and estrogen receptors

Exclusion Criteria:

• not eligible for pregnancy or delivery
• evidence of suspected extrauterine or distant metastasis
• complicated with any other malignancy
• severe medical complications
• contraindication of oral progestin
• uncontrolled epilepsy, central nervous system disease or mental disorder history in patients which Influence clinical research compliance judging by the researcher.